查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1714641

疫苗市場按類型、疫苗組合、供應來源、疫苗分類、給藥途徑、適應症、年齡層、最終用戶分類 - 2025-2030 年全球預測

Vaccines Market by Type, Vaccine Combination, Source, Vaccine Classification, Route of Administration, Indication, Age Group, End User - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 192 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計疫苗市場規模在 2024 年將達到 837.9 億美元，到 2025 年將以 7.72% 的複合年成長率成長至 901.9 億美元，到 2030 年將達到 1309.4 億美元。

主要市場統計數據
基準年2024年 837.9億美元
預計年份：2025年 901.9億美元
預測年份 2030 1309.4億美元
複合年成長率（%） 7.72%

過去十年，疫苗產業經歷了前所未有的成長和轉型。技術進步、對全球衛生安全的日益成長的擔憂以及對新興疾病快速反應的需求不斷增加共同再形成了市場。當今的疫苗格局不僅由突破性的科學創新決定，還由不斷變化的患者需求和動態的監管格局決定。研究人員和行業專家正在以一種上一代人無法想像的方式進行合作，共用見解和最佳實踐，以應對複雜的健康挑戰。

這份全面的執行摘要探討並概述了將繼續重新定義疫苗研究和製造的關鍵趨勢、市場促進因素和顛覆性創新。我們檢驗改進的製造流程、新的交付平台和整合的數位技術如何加速疫苗開發的步伐。當公共衛生議題成為全球政策討論的焦點時，相關人員面臨的挑戰是如何保持敏捷和應對力。該報告提供了深入的分析，以幫助您做出策略決策並在競爭日益激烈的全球市場中最大限度地發揮您的潛力。

改變疫苗市場

在科學突破、投資增加和策略調整的推動下，疫苗產業正在經歷轉型變革。傳訊RNA技術創新和快速適應性實驗室測試等最新發展正在重新定義傳統的疫苗開發方法。這一轉變是由簡化的監管流程推動的，該流程可確保安全，而不會延遲關鍵的核准。

公共和私營部門正在利用數位技術和數據分析的力量，使研究更有效率、更準確地預測需求。新興趨勢包括針對特定人口統計和疾病特徵的個人化疫苗接種策略，以及採用先進的製造技術來提高生產能力。跨國合作和跨學科夥伴關係正在進一步加速這些創新，使疫苗領域比以往任何時候都更具回應能力。隨著這些動態變化，行業領導者正在尋求透過增強科學嚴謹性、提高業務效率和堅定不移地致力於應對全球健康挑戰來最大限度地利用商業機會。

深入了解動態市場動態的市場區隔

對疫苗市場的深入研究揭示了複雜的細分結構，為了解該行業的各個要素提供了寶貴的見解。依疫苗類型細分包括去活化疫苗、減毒疫苗、傳訊RNA疫苗、次單元疫苗、重組疫苗、多醣體疫苗、結合疫苗、類毒素疫苗和病毒載體疫苗。同樣重要的是按疫苗組合進行細分，區分單價疫苗和多效價疫苗。此外，在來源類別中區分人用疫苗和獸用疫苗可以進行更詳細的分析。此外，市場分為預防性疫苗和治療性疫苗，滿足預防和治療需求。

給藥途徑也是一個重要因素，可以包括肌肉注射、鼻腔內注射、口服和皮下給藥，適應症分為感染疾病疾病和非感染疾病。感染疾病又細分為肝炎、人類乳突病毒、流感、麻疹、腦膜炎球菌疾病、百日咳、肺炎球菌疾病、狂犬病、輪狀病毒、破傷風、水痘等，其中特別值得注意。同時，在非傳染性疾病領域，自體免疫疾病和癌症疫苗等領域正受到關注。這些都透過區分成人、老年人和兒童（後者進一步分為嬰兒）的人口統計見解以及涵蓋學術和研究機構、醫院診所、疫苗接種中心等的最終用戶分類來補充。

目錄

第1章 引言

第2章調查方法

第3章執行摘要

第4章 市場概述

第5章 市場洞察

  • 市場動態
    • 驅動程式
      • 感染疾病的傳播增加了對疫苗的需求
      • 各國政府支持疫苗接種計畫的措施和措施正在不斷擴大
      • 社交媒體和數位平台傳播有關疫苗益處的認知和教育
    • 限制因素
      • 疫苗研發和經銷成本高昂
    • 機會
      • 疫苗生產和分發的技術進步
      • 增加先進疫苗製劑研發活動的投資
    • 任務
      • 因應疫苗核准複雜而漫長的監管環境
  • 市場區隔分析
    • 類型：傳訊RNA疫苗非常有效，因此非常重要
    • 最終用戶：醫院和診所的疫苗採用率有所提高，以應對緊急公共衛生事件
  • 波特五力分析
  • PESTEL分析
    • 政治
    • 經濟
    • 社會
    • 科技
    • 法律
    • 環境

第6章疫苗市場（按類型）

  • 介紹
  • 去活化疫苗
  • 減毒活疫苗
  • 傳訊RNA疫苗
  • 次單元、重組疫苗、多醣體疫苗和結合疫苗
  • 類毒素疫苗
  • 病毒載體疫苗

第7章疫苗市場（依疫苗分類）

  • 介紹
  • 單價疫苗
  • 多效價疫苗

8. 疫苗市場（依供應來源）

  • 介紹
  • 人類疫苗
  • 獸用疫苗

9. 疫苗市場（依疫苗類別）

  • 介紹
  • 預防性疫苗
  • 治療性疫苗

第10章 疫苗市場（依接種途徑）

  • 介紹
  • 肌肉注射
  • 鼻內
  • 口服
  • 皮下

第11章疫苗市場（按適應症）

  • 介紹
  • 感染疾病
    • 肝炎
    • 人類乳突病毒
    • 流感
    • 麻疹
    • 病菌感染
    • 百日咳
    • 肺炎鏈球菌感染
    • 狂犬病
    • 輪狀病毒
    • 破傷風
    • 水痘
  • 非傳染性疾病
    • 自體免疫疾病
    • 癌症疫苗

第12章 疫苗市場（依年齡層）

  • 介紹
  • 成人
  • 老年人
  • 孩子們
    • 嬰兒
    • 嬰兒

第13章疫苗市場（依最終用戶）

  • 介紹
  • 學術研究所
  • 醫院和診所
  • 疫苗接種中心

14.美洲疫苗市場

  • 介紹
  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

15. 亞太疫苗市場

  • 介紹
  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

16.歐洲、中東和非洲疫苗市場

  • 介紹
  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第17章競爭格局

  • 2024年市場佔有率分析
  • 2024年FPNV定位矩陣
  • 競爭情境分析
  • 戰略分析與建議

公司名單

  • Abbott Laboratories
  • Astellas Pharma Inc.
  • AstraZeneca PLC
  • Bavarian Nordic A/S
  • Bharat BIoTech Ltd.
  • Biological E. Limited
  • BioNTech SE
  • Blue Lake BIoTechnology
  • Capricor Therapeutics, Inc.
  • Chongqing Zhifei Biological Products Co., Ltd.
  • CSL Limited
  • CureVac NV
  • Daiichi Sankyo Company, Limited.
  • Gennova Biopharmaceuticals Limited
  • GlaxoSmithKline PLC
  • Haffkine Bio-Pharmaceutical Corporation Ltd
  • Incepta Pharmaceuticals Ltd.
  • Inovio Pharmaceuticals, Inc.
  • Johnson & Johnson Services, Inc.
  • Merck & Co., Inc.
  • Moderna, Inc.
  • Novavax, Inc.
  • Pfizer Inc.
  • Sanofi SA
  • Serum Institute of India Pvt. Ltd.
  • Sinovac BIoTech Ltd.
  • Takeda Pharmaceutical Company Limited
  • VBI Vaccines Inc.
  • Versatope Therapeutics
  • Zydus Lifesciences Limited
Product Code: MRR-434CCDA0513E

The Vaccines Market was valued at USD 83.79 billion in 2024 and is projected to grow to USD 90.19 billion in 2025, with a CAGR of 7.72%, reaching USD 130.94 billion by 2030.

KEY MARKET STATISTICS
Base Year [2024] USD 83.79 billion
Estimated Year [2025] USD 90.19 billion
Forecast Year [2030] USD 130.94 billion
CAGR (%) 7.72%

The vaccine industry has witnessed unparalleled growth and transformation over the past decade. Advances in technology, a heightened focus on global health security, and an increased demand for rapid responses to emerging diseases have collectively reshaped the market. Today's vaccine landscape is not only defined by breakthrough scientific innovations but also by evolving patient needs and dynamic regulatory environments. Researchers and industry experts are working together in ways that were unthinkable a generation ago, sharing insights and best practices to combat complex health challenges.

This comprehensive executive summary sets the stage by exploring key trends, market drivers, and disruptive innovations that continue to redefine vaccine research and production. It examines how improved manufacturing processes, novel delivery platforms, and integrated digital technologies have accelerated the pace of vaccine development. In an age where public health concerns are at the forefront of global policy discussions, stakeholders are challenged to remain agile and responsive. This report provides an in-depth analysis designed to inform strategic decision-making and maximize potential in an increasingly competitive global marketplace.

Transformative Shifts in the Vaccine Landscape

The vaccine sector is experiencing transformative shifts driven by scientific breakthroughs, increased investments, and strategic realignments. Recent developments, such as messenger RNA innovations and rapid adaptive clinical trials, have redefined traditional vaccine development practices. This shift is bolstered by streamlined regulatory processes that ensure safety without delaying critical approvals.

Public and private sectors are harnessing the power of digital technologies and data analytics to improve research efficiency and forecast demand accurately. Emerging trends include a focus on personalized immunization strategies that cater to specific demographics and disease profiles, as well as the adoption of advanced manufacturing techniques that bolster production capacities. Collaborative research across international borders and interdisciplinary partnerships has further amplified these innovations, making the vaccine landscape more responsive than ever. With these dynamic changes, industry leaders are set to capitalize on opportunities driven by enhanced scientific rigor, operational efficiencies, and an unwavering commitment to addressing global health challenges.

In-depth Segmentation Insights Driving Market Dynamics

A thorough examination of the vaccine market reveals a complex segmentation structure that provides valuable insights into the diverse elements of the industry. The segmentation based on type dissects the market into inactivated vaccines, live-attenuated vaccines, messenger RNA vaccines, as well as subunit, recombinant, polysaccharide, conjugate, toxoid, and viral vector vaccines. Equally critical is the segmentation based on vaccine combination, which distinguishes between mono-valent and multi-valent vaccines. A further layer of analysis is provided by distinguishing between human and veterinary vaccines under the source category. Moreover, the market is methodically classified into preventive vaccines and therapeutic vaccines, addressing both prophylactic and treatment-oriented needs.

The route of administration is another key factor, covering intramuscular, intranasal, oral, and subcutaneous methods, while the indication-based segmentation divides the market into infectious diseases and non-infectious diseases. Infectious diseases merit special attention, as they are further subdivided into conditions such as hepatitis, human papillomavirus, influenza, measles, meningococcal disease, pertussis, pneumococcal disease, rabies, rotavirus, tetanus, and varicella. Meanwhile, non-infectious diseases highlight segments like autoimmune diseases and cancer vaccines. Complementing these are demographic insights that differentiate between adult, geriatric, and pediatric populations-the latter further broken down into infants and toddlers-and end user classifications that encompass academic and research institutes, hospitals and clinics, as well as vaccination centers.

Based on Type, market is studied across Inactivated Vaccines, Live-Attenuated Vaccines, Messenger RNA Vaccines, Subunit, Recombinant, Polysaccharide, & Conjugate Vaccines, Toxoid Vaccines, and Viral Vector Vaccines.

Based on Vaccine Combination, market is studied across Mono-Valent Vaccines and Multi-Valent Vaccines.

Based on Source, market is studied across Human Vaccines and Veterinary Vaccines.

Based on Vaccine Classification, market is studied across Preventive Vaccines and Therapeutic Vaccines.

Based on Route of Administration, market is studied across Intramuscular, Intranasal, Oral, and Subcutaneous.

Based on Indication, market is studied across Infectious Diseases and Non-Infectious Diseases. The Infectious Diseases is further studied across Hepatitis, Human Papillomavirus, Influenza, Measles, Meningococcal Disease, Pertussis, Pneumococcal Disease, Rabies, Rotavirus, Tetanus, and Varicella. The Non-Infectious Diseases is further studied across Autoimmune Diseases and Cancer Vaccines.

Based on Age Group, market is studied across Adult, Geriatric, and Pediatric. The Pediatric is further studied across Infants and Toddlers.

Based on End User, market is studied across Academic & Research Institutes, Hospitals & Clinics, and Vaccination Centers.

Regional Market Perspectives and Emerging Trends

The global vaccine market exhibits distinct variations across regions, each characterized by unique challenges and opportunities that contribute to a dynamic industry landscape. In the Americas, the market benefits from a mature infrastructure supported by advanced research facilities and a history of successful immunization programs. By contrast, in regions spanning Europe, the Middle East, and Africa, a blend of established healthcare systems and rapidly emerging markets fosters both continuity in research and innovation in deployment strategies.

The Asia-Pacific region stands out as a burgeoning powerhouse, where strong governmental support, increasing investments in healthcare infrastructure, and accelerating public-private partnerships are driving exponential growth. These regional variations compel stakeholders to tailor their strategies to local market conditions while remaining informed of global trends. Assessing regional insights ensures that emerging opportunities are comprehensively addressed, whether by leveraging the technological prowess of the Americas, the progressive reforms in Europe, the Middle East, and Africa, or the dynamic expansion seen in the Asia-Pacific region.

Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

Key Players Shaping the Future of Vaccines

The competitive landscape in the vaccine market is defined by a host of influential companies that drive innovation and market growth on a global scale. Industry leaders such as Abbott Laboratories, Astellas Pharma Inc., AstraZeneca PLC, and Bavarian Nordic A/S have long been recognized for setting high standards in safety and efficacy. Equally significant are Bharat Biotech Ltd. and Biological E. Limited, whose cost-effective and scalable vaccine solutions have opened new avenues in emerging markets. Advanced biotech firms like BioNTech SE and Blue Lake Biotechnology are at the forefront of developing cutting-edge messenger RNA platforms, while Capricor Therapeutics, Inc., Chongqing Zhifei Biological Products Co., Ltd., CSL Limited, and CureVac N.V. are rapidly gaining ground in research and development.

The landscape is further enhanced by the contributions of Daiichi Sankyo Company, Limited., Gennova Biopharmaceuticals Limited, and GlaxoSmithKline PLC, alongside renowned institutions such as Haffkine Bio-Pharmaceutical Corporation Ltd, Incepta Pharmaceuticals Ltd., Inovio Pharmaceuticals, Inc., Johnson & Johnson Services, Inc., and Merck & Co., Inc. Innovative companies like Moderna, Inc., Novavax, Inc., Pfizer Inc., Sanofi S.A., and Serum Institute of India Pvt. Ltd. also play pivotal roles, complemented by Sinovac Biotech Ltd., Takeda Pharmaceutical Company Limited, VBI Vaccines Inc., Versatope Therapeutics, and Zydus Lifesciences Limited. Collectively, these organizations harness sophisticated technologies, cutting-edge research, and expansive distribution networks to drive market evolution and deliver impactful health solutions worldwide.

The report delves into recent significant developments in the Vaccines Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Astellas Pharma Inc., AstraZeneca PLC, Bavarian Nordic A/S, Bharat Biotech Ltd., Biological E. Limited, BioNTech SE, Blue Lake Biotechnology, Capricor Therapeutics, Inc., Chongqing Zhifei Biological Products Co., Ltd., CSL Limited, CureVac N.V., Daiichi Sankyo Company, Limited., Gennova Biopharmaceuticals Limited, GlaxoSmithKline PLC, Haffkine Bio-Pharmaceutical Corporation Ltd, Incepta Pharmaceuticals Ltd., Inovio Pharmaceuticals, Inc., Johnson & Johnson Services, Inc., Merck & Co., Inc., Moderna, Inc., Novavax, Inc., Pfizer Inc., Sanofi S.A., Serum Institute of India Pvt. Ltd., Sinovac Biotech Ltd., Takeda Pharmaceutical Company Limited, VBI Vaccines Inc., Versatope Therapeutics, and Zydus Lifesciences Limited. Actionable Recommendations for Industry Leaders

Industry leaders operating in the vaccine sector are encouraged to adopt a proactive approach that balances innovation with operational excellence. To stay competitive, it is essential to invest in modern research and development infrastructure and establish cross-functional partnerships that can accelerate the translation of scientific discovery into market-ready solutions. Embracing digital transformation-by integrating advanced data analytics and real-time monitoring systems-will enhance decision-making processes and facilitate refined market insights.

Furthermore, leaders should prioritize regulatory agility by actively engaging with policy makers to streamline approval mechanisms without compromising stringent safety standards. Strengthening supply chain processes and diversifying manufacturing capabilities will hedge against unforeseen disruptions while ensuring consistent product availability. Collaborative efforts with academic institutions, hospitals, and vaccination centers can further solidify market presence and expand outreach. By cultivating a culture of continuous improvement, transparent communication, and robust risk management, industry stakeholders can not only mitigate emerging challenges but also harness new opportunities in an evolving global landscape.

Conclusive Reflections on the Vaccine Industry

The vaccine market is at a pivotal juncture, marked by rapid scientific advancements and ever-evolving market demands. This executive summary has illustrated how the nuanced segmentation across vaccine type, combination, source, classification, route of administration, and indication provides a detailed framework for understanding market dynamics. In addition, demographic factors and end user insights enrich the overall analysis, offering a multi-dimensional view of the challenges and opportunities that lie ahead.

Regional insights reveal that mature markets, emerging economies, and dynamic growth regions each offer unique prospects that must be strategically leveraged. The sustained innovation and agility demonstrated by key industry players underlie a resilient ecosystem that is capable of responding to both current and future public health needs. Ultimately, the synthesis of these insights reinforces the importance of informed decision-making and strategic investments, empowering stakeholders to navigate an increasingly competitive and complex landscape with confidence and precision.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increasing prevalence of infectious diseases raising the need for vaccines
      • 5.1.1.2. Growing government initiatives and policies supporting vaccination programs around the world
      • 5.1.1.3. Social media and digital platforms amplifying awareness and education about the benefits of vaccines
    • 5.1.2. Restraints
      • 5.1.2.1. High development and distribution costs associated with vaccines
    • 5.1.3. Opportunities
      • 5.1.3.1. Technological advancements in vaccine production and distribution
      • 5.1.3.2. Rising investments in research and development activities for advanced vaccine formulation
    • 5.1.4. Challenges
      • 5.1.4.1. Navigating the complex and time-consuming regulatory landscape for vaccine approval
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Type: Critical need for messenger RNA vaccines due to their high effectiveness
    • 5.2.2. End user: Rising adoption of vaccines across hospitals & clinics for emergency public health responses.
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Vaccines Market, by Type

  • 6.1. Introduction
  • 6.2. Inactivated Vaccines
  • 6.3. Live-Attenuated Vaccines
  • 6.4. Messenger RNA Vaccines
  • 6.5. Subunit, Recombinant, Polysaccharide, & Conjugate Vaccines
  • 6.6. Toxoid Vaccines
  • 6.7. Viral Vector Vaccines

7. Vaccines Market, by Vaccine Combination

  • 7.1. Introduction
  • 7.2. Mono-Valent Vaccines
  • 7.3. Multi-Valent Vaccines

8. Vaccines Market, by Source

  • 8.1. Introduction
  • 8.2. Human Vaccines
  • 8.3. Veterinary Vaccines

9. Vaccines Market, by Vaccine Classification

  • 9.1. Introduction
  • 9.2. Preventive Vaccines
  • 9.3. Therapeutic Vaccines

10. Vaccines Market, by Route of Administration

  • 10.1. Introduction
  • 10.2. Intramuscular
  • 10.3. Intranasal
  • 10.4. Oral
  • 10.5. Subcutaneous

11. Vaccines Market, by Indication

  • 11.1. Introduction
  • 11.2. Infectious Diseases
    • 11.2.1. Hepatitis
    • 11.2.2. Human Papillomavirus
    • 11.2.3. Influenza
    • 11.2.4. Measles
    • 11.2.5. Meningococcal Disease
    • 11.2.6. Pertussis
    • 11.2.7. Pneumococcal Disease
    • 11.2.8. Rabies
    • 11.2.9. Rotavirus
    • 11.2.10. Tetanus
    • 11.2.11. Varicella
  • 11.3. Non-Infectious Diseases
    • 11.3.1. Autoimmune Diseases
    • 11.3.2. Cancer Vaccines

12. Vaccines Market, by Age Group

  • 12.1. Introduction
  • 12.2. Adult
  • 12.3. Geriatric
  • 12.4. Pediatric
    • 12.4.1. Infants
    • 12.4.2. Toddlers

13. Vaccines Market, by End User

  • 13.1. Introduction
  • 13.2. Academic & Research Institutes
  • 13.3. Hospitals & Clinics
  • 13.4. Vaccination Centers

14. Americas Vaccines Market

  • 14.1. Introduction
  • 14.2. Argentina
  • 14.3. Brazil
  • 14.4. Canada
  • 14.5. Mexico
  • 14.6. United States

15. Asia-Pacific Vaccines Market

  • 15.1. Introduction
  • 15.2. Australia
  • 15.3. China
  • 15.4. India
  • 15.5. Indonesia
  • 15.6. Japan
  • 15.7. Malaysia
  • 15.8. Philippines
  • 15.9. Singapore
  • 15.10. South Korea
  • 15.11. Taiwan
  • 15.12. Thailand
  • 15.13. Vietnam

16. Europe, Middle East & Africa Vaccines Market

  • 16.1. Introduction
  • 16.2. Denmark
  • 16.3. Egypt
  • 16.4. Finland
  • 16.5. France
  • 16.6. Germany
  • 16.7. Israel
  • 16.8. Italy
  • 16.9. Netherlands
  • 16.10. Nigeria
  • 16.11. Norway
  • 16.12. Poland
  • 16.13. Qatar
  • 16.14. Russia
  • 16.15. Saudi Arabia
  • 16.16. South Africa
  • 16.17. Spain
  • 16.18. Sweden
  • 16.19. Switzerland
  • 16.20. Turkey
  • 16.21. United Arab Emirates
  • 16.22. United Kingdom

17. Competitive Landscape

  • 17.1. Market Share Analysis, 2024
  • 17.2. FPNV Positioning Matrix, 2024
  • 17.3. Competitive Scenario Analysis
    • 17.3.1. Mankind Pharma acquires Bharat Serums and Vaccines (BSV) for strategic expansion in Women's Health and Fertility market
    • 17.3.2. Sanofi and Novavax partner to co-commercialize new COVID-19 vaccine and develop flu-COVID combo shot
    • 17.3.3. CureVac and MD Anderson team up to develop mRNA-based cancer vaccines, paving the way for advanced cancer treatments
    • 17.3.4. Bavarian Nordic launches mpox vaccine in the U.S., boosting preventive healthcare and market innovation
    • 17.3.5. Bharat Biotech and Bilthoven Biologicals unite to boost global polio eradication efforts with enhanced OPV production
    • 17.3.6. Takeda forms partnership to boost global access to dengue vaccine, targeting hard-hit regions
    • 17.3.7. AstraZeneca bolsters vaccine capabilities by acquiring biotechnology firm Icosavax
    • 17.3.8. Serum Institute of India Partners with CEPI to increase global vaccine accessibility during epidemics
    • 17.3.9. GSK partners with Zhifei to exclusively distribute shingles vaccine Shingrix in China, aiming to enhance public health and vaccine access
    • 17.3.10. Janssen and Sanofi join forces to develop vaccine program to address unmet medical needs
  • 17.4. Strategy Analysis & Recommendation
    • 17.4.1. AstraZeneca PLC
    • 17.4.2. Pfizer Inc.
    • 17.4.3. GlaxoSmithKline PLC
    • 17.4.4. Merck & Co., Inc.
    • 17.4.5. Sanofi S.A.

Companies Mentioned

  • 1. Abbott Laboratories
  • 2. Astellas Pharma Inc.
  • 3. AstraZeneca PLC
  • 4. Bavarian Nordic A/S
  • 5. Bharat Biotech Ltd.
  • 6. Biological E. Limited
  • 7. BioNTech SE
  • 8. Blue Lake Biotechnology
  • 9. Capricor Therapeutics, Inc.
  • 10. Chongqing Zhifei Biological Products Co., Ltd.
  • 11. CSL Limited
  • 12. CureVac N.V.
  • 13. Daiichi Sankyo Company, Limited.
  • 14. Gennova Biopharmaceuticals Limited
  • 15. GlaxoSmithKline PLC
  • 16. Haffkine Bio-Pharmaceutical Corporation Ltd
  • 17. Incepta Pharmaceuticals Ltd.
  • 18. Inovio Pharmaceuticals, Inc.
  • 19. Johnson & Johnson Services, Inc.
  • 20. Merck & Co., Inc.
  • 21. Moderna, Inc.
  • 22. Novavax, Inc.
  • 23. Pfizer Inc.
  • 24. Sanofi S.A.
  • 25. Serum Institute of India Pvt. Ltd.
  • 26. Sinovac Biotech Ltd.
  • 27. Takeda Pharmaceutical Company Limited
  • 28. VBI Vaccines Inc.
  • 29. Versatope Therapeutics
  • 30. Zydus Lifesciences Limited

LIST OF FIGURES

  • FIGURE 1. VACCINES MARKET MULTI-CURRENCY
  • FIGURE 2. VACCINES MARKET MULTI-LANGUAGE
  • FIGURE 3. VACCINES MARKET RESEARCH PROCESS
  • FIGURE 4. VACCINES MARKET SIZE, 2024 VS 2030
  • FIGURE 5. GLOBAL VACCINES MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 6. GLOBAL VACCINES MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 7. GLOBAL VACCINES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL VACCINES MARKET SIZE, BY TYPE, 2024 VS 2030 (%)
  • FIGURE 9. GLOBAL VACCINES MARKET SIZE, BY TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL VACCINES MARKET SIZE, BY VACCINE COMBINATION, 2024 VS 2030 (%)
  • FIGURE 11. GLOBAL VACCINES MARKET SIZE, BY VACCINE COMBINATION, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL VACCINES MARKET SIZE, BY SOURCE, 2024 VS 2030 (%)
  • FIGURE 13. GLOBAL VACCINES MARKET SIZE, BY SOURCE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 14. GLOBAL VACCINES MARKET SIZE, BY VACCINE CLASSIFICATION, 2024 VS 2030 (%)
  • FIGURE 15. GLOBAL VACCINES MARKET SIZE, BY VACCINE CLASSIFICATION, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 16. GLOBAL VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2030 (%)
  • FIGURE 17. GLOBAL VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 18. GLOBAL VACCINES MARKET SIZE, BY INDICATION, 2024 VS 2030 (%)
  • FIGURE 19. GLOBAL VACCINES MARKET SIZE, BY INDICATION, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 20. GLOBAL VACCINES MARKET SIZE, BY AGE GROUP, 2024 VS 2030 (%)
  • FIGURE 21. GLOBAL VACCINES MARKET SIZE, BY AGE GROUP, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 22. GLOBAL VACCINES MARKET SIZE, BY END USER, 2024 VS 2030 (%)
  • FIGURE 23. GLOBAL VACCINES MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 24. AMERICAS VACCINES MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 25. AMERICAS VACCINES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 26. UNITED STATES VACCINES MARKET SIZE, BY STATE, 2024 VS 2030 (%)
  • FIGURE 27. UNITED STATES VACCINES MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 28. ASIA-PACIFIC VACCINES MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 29. ASIA-PACIFIC VACCINES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 30. EUROPE, MIDDLE EAST & AFRICA VACCINES MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 31. EUROPE, MIDDLE EAST & AFRICA VACCINES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 32. VACCINES MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 33. VACCINES MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. VACCINES MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL VACCINES MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL VACCINES MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL VACCINES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. VACCINES MARKET DYNAMICS
  • TABLE 7. GLOBAL VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL VACCINES MARKET SIZE, BY INACTIVATED VACCINES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL VACCINES MARKET SIZE, BY LIVE-ATTENUATED VACCINES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL VACCINES MARKET SIZE, BY MESSENGER RNA VACCINES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL VACCINES MARKET SIZE, BY SUBUNIT, RECOMBINANT, POLYSACCHARIDE, & CONJUGATE VACCINES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL VACCINES MARKET SIZE, BY TOXOID VACCINES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL VACCINES MARKET SIZE, BY VIRAL VECTOR VACCINES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL VACCINES MARKET SIZE, BY VACCINE COMBINATION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL VACCINES MARKET SIZE, BY MONO-VALENT VACCINES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL VACCINES MARKET SIZE, BY MULTI-VALENT VACCINES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL VACCINES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL VACCINES MARKET SIZE, BY HUMAN VACCINES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL VACCINES MARKET SIZE, BY VETERINARY VACCINES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL VACCINES MARKET SIZE, BY VACCINE CLASSIFICATION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL VACCINES MARKET SIZE, BY PREVENTIVE VACCINES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL VACCINES MARKET SIZE, BY THERAPEUTIC VACCINES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL VACCINES MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL VACCINES MARKET SIZE, BY INTRANASAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL VACCINES MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 27. GLOBAL VACCINES MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 28. GLOBAL VACCINES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 29. GLOBAL VACCINES MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 30. GLOBAL VACCINES MARKET SIZE, BY HEPATITIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 31. GLOBAL VACCINES MARKET SIZE, BY HUMAN PAPILLOMAVIRUS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 32. GLOBAL VACCINES MARKET SIZE, BY INFLUENZA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 33. GLOBAL VACCINES MARKET SIZE, BY MEASLES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 34. GLOBAL VACCINES MARKET SIZE, BY MENINGOCOCCAL DISEASE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 35. GLOBAL VACCINES MARKET SIZE, BY PERTUSSIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 36. GLOBAL VACCINES MARKET SIZE, BY PNEUMOCOCCAL DISEASE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 37. GLOBAL VACCINES MARKET SIZE, BY RABIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 38. GLOBAL VACCINES MARKET SIZE, BY ROTAVIRUS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 39. GLOBAL VACCINES MARKET SIZE, BY TETANUS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 40. GLOBAL VACCINES MARKET SIZE, BY VARICELLA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 41. GLOBAL VACCINES MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 42. GLOBAL VACCINES MARKET SIZE, BY NON-INFECTIOUS DISEASES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 43. GLOBAL VACCINES MARKET SIZE, BY AUTOIMMUNE DISEASES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 44. GLOBAL VACCINES MARKET SIZE, BY CANCER VACCINES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 45. GLOBAL VACCINES MARKET SIZE, BY NON-INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 46. GLOBAL VACCINES MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 47. GLOBAL VACCINES MARKET SIZE, BY ADULT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 48. GLOBAL VACCINES MARKET SIZE, BY GERIATRIC, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 49. GLOBAL VACCINES MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 50. GLOBAL VACCINES MARKET SIZE, BY INFANTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 51. GLOBAL VACCINES MARKET SIZE, BY TODDLERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 52. GLOBAL VACCINES MARKET SIZE, BY PEDIATRIC, 2018-2030 (USD MILLION)
  • TABLE 53. GLOBAL VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 54. GLOBAL VACCINES MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 55. GLOBAL VACCINES MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 56. GLOBAL VACCINES MARKET SIZE, BY VACCINATION CENTERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 57. AMERICAS VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 58. AMERICAS VACCINES MARKET SIZE, BY VACCINE COMBINATION, 2018-2030 (USD MILLION)
  • TABLE 59. AMERICAS VACCINES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 60. AMERICAS VACCINES MARKET SIZE, BY VACCINE CLASSIFICATION, 2018-2030 (USD MILLION)
  • TABLE 61. AMERICAS VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 62. AMERICAS VACCINES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 63. AMERICAS VACCINES MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 64. AMERICAS VACCINES MARKET SIZE, BY NON-INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 65. AMERICAS VACCINES MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 66. AMERICAS VACCINES MARKET SIZE, BY PEDIATRIC, 2018-2030 (USD MILLION)
  • TABLE 67. AMERICAS VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 68. AMERICAS VACCINES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 69. ARGENTINA VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 70. ARGENTINA VACCINES MARKET SIZE, BY VACCINE COMBINATION, 2018-2030 (USD MILLION)
  • TABLE 71. ARGENTINA VACCINES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 72. ARGENTINA VACCINES MARKET SIZE, BY VACCINE CLASSIFICATION, 2018-2030 (USD MILLION)
  • TABLE 73. ARGENTINA VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 74. ARGENTINA VACCINES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 75. ARGENTINA VACCINES MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 76. ARGENTINA VACCINES MARKET SIZE, BY NON-INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 77. ARGENTINA VACCINES MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 78. ARGENTINA VACCINES MARKET SIZE, BY PEDIATRIC, 2018-2030 (USD MILLION)
  • TABLE 79. ARGENTINA VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 80. BRAZIL VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 81. BRAZIL VACCINES MARKET SIZE, BY VACCINE COMBINATION, 2018-2030 (USD MILLION)
  • TABLE 82. BRAZIL VACCINES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 83. BRAZIL VACCINES MARKET SIZE, BY VACCINE CLASSIFICATION, 2018-2030 (USD MILLION)
  • TABLE 84. BRAZIL VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 85. BRAZIL VACCINES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 86. BRAZIL VACCINES MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 87. BRAZIL VACCINES MARKET SIZE, BY NON-INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 88. BRAZIL VACCINES MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 89. BRAZIL VACCINES MARKET SIZE, BY PEDIATRIC, 2018-2030 (USD MILLION)
  • TABLE 90. BRAZIL VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 91. CANADA VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 92. CANADA VACCINES MARKET SIZE, BY VACCINE COMBINATION, 2018-2030 (USD MILLION)
  • TABLE 93. CANADA VACCINES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 94. CANADA VACCINES MARKET SIZE, BY VACCINE CLASSIFICATION, 2018-2030 (USD MILLION)
  • TABLE 95. CANADA VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 96. CANADA VACCINES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 97. CANADA VACCINES MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 98. CANADA VACCINES MARKET SIZE, BY NON-INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 99. CANADA VACCINES MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 100. CANADA VACCINES MARKET SIZE, BY PEDIATRIC, 2018-2030 (USD MILLION)
  • TABLE 101. CANADA VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 102. MEXICO VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 103. MEXICO VACCINES MARKET SIZE, BY VACCINE COMBINATION, 2018-2030 (USD MILLION)
  • TABLE 104. MEXICO VACCINES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 105. MEXICO VACCINES MARKET SIZE, BY VACCINE CLASSIFICATION, 2018-2030 (USD MILLION)
  • TABLE 106. MEXICO VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 107. MEXICO VACCINES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 108. MEXICO VACCINES MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 109. MEXICO VACCINES MARKET SIZE, BY NON-INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 110. MEXICO VACCINES MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 111. MEXICO VACCINES MARKET SIZE, BY PEDIATRIC, 2018-2030 (USD MILLION)
  • TABLE 112. MEXICO VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 113. UNITED STATES VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 114. UNITED STATES VACCINES MARKET SIZE, BY VACCINE COMBINATION, 2018-2030 (USD MILLION)
  • TABLE 115. UNITED STATES VACCINES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 116. UNITED STATES VACCINES MARKET SIZE, BY VACCINE CLASSIFICATION, 2018-2030 (USD MILLION)
  • TABLE 117. UNITED STATES VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 118. UNITED STATES VACCINES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 119. UNITED STATES VACCINES MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 120. UNITED STATES VACCINES MARKET SIZE, BY NON-INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 121. UNITED STATES VACCINES MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 122. UNITED STATES VACCINES MARKET SIZE, BY PEDIATRIC, 2018-2030 (USD MILLION)
  • TABLE 123. UNITED STATES VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 124. UNITED STATES VACCINES MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 125. ASIA-PACIFIC VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 126. ASIA-PACIFIC VACCINES MARKET SIZE, BY VACCINE COMBINATION, 2018-2030 (USD MILLION)
  • TABLE 127. ASIA-PACIFIC VACCINES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 128. ASIA-PACIFIC VACCINES MARKET SIZE, BY VACCINE CLASSIFICATION, 2018-2030 (USD MILLION)
  • TABLE 129. ASIA-PACIFIC VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 130. ASIA-PACIFIC VACCINES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 131. ASIA-PACIFIC VACCINES MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 132. ASIA-PACIFIC VACCINES MARKET SIZE, BY NON-INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 133. ASIA-PACIFIC VACCINES MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 134. ASIA-PACIFIC VACCINES MARKET SIZE, BY PEDIATRIC, 2018-2030 (USD MILLION)
  • TABLE 135. ASIA-PACIFIC VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 136. ASIA-PACIFIC VACCINES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 137. AUSTRALIA VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 138. AUSTRALIA VACCINES MARKET SIZE, BY VACCINE COMBINATION, 2018-2030 (USD MILLION)
  • TABLE 139. AUSTRALIA VACCINES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 140. AUSTRALIA VACCINES MARKET SIZE, BY VACCINE CLASSIFICATION, 2018-2030 (USD MILLION)
  • TABLE 141. AUSTRALIA VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 142. AUSTRALIA VACCINES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 143. AUSTRALIA VACCINES MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 144. AUSTRALIA VACCINES MARKET SIZE, BY NON-INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 145. AUSTRALIA VACCINES MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 146. AUSTRALIA VACCINES MARKET SIZE, BY PEDIATRIC, 2018-2030 (USD MILLION)
  • TABLE 147. AUSTRALIA VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 148. CHINA VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 149. CHINA VACCINES MARKET SIZE, BY VACCINE COMBINATION, 2018-2030 (USD MILLION)
  • TABLE 150. CHINA VACCINES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 151. CHINA VACCINES MARKET SIZE, BY VACCINE CLASSIFICATION, 2018-2030 (USD MILLION)
  • TABLE 152. CHINA VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 153. CHINA VACCINES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 154. CHINA VACCINES MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 155. CHINA VACCINES MARKET SIZE, BY NON-INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 156. CHINA VACCINES MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 157. CHINA VACCINES MARKET SIZE, BY PEDIATRIC, 2018-2030 (USD MILLION)
  • TABLE 158. CHINA VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 159. INDIA VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 160. INDIA VACCINES MARKET SIZE, BY VACCINE COMBINATION, 2018-2030 (USD MILLION)
  • TABLE 161. INDIA VACCINES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 162. INDIA VACCINES MARKET SIZE, BY VACCINE CLASSIFICATION, 2018-2030 (USD MILLION)
  • TABLE 163. INDIA VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 164. INDIA VACCINES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 165. INDIA VACCINES MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 166. INDIA VACCINES MARKET SIZE, BY NON-INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 167. INDIA VACCINES MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 168. INDIA VACCINES MARKET SIZE, BY PEDIATRIC, 2018-2030 (USD MILLION)
  • TABLE 169. INDIA VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 170. INDONESIA VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 171. INDONESIA VACCINES MARKET SIZE, BY VACCINE COMBINATION, 2018-2030 (USD MILLION)
  • TABLE 172. INDONESIA VACCINES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 173. INDONESIA VACCINES MARKET SIZE, BY VACCINE CLASSIFICATION, 2018-2030 (USD MILLION)
  • TABLE 174. INDONESIA VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 175. INDONESIA VACCINES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 176. INDONESIA VACCINES MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 177. INDONESIA VACCINES MARKET SIZE, BY NON-INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 178. INDONESIA VACCINES MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 179. INDONESIA VACCINES MARKET SIZE, BY PEDIATRIC, 2018-2030 (USD MILLION)
  • TABLE 180. INDONESIA VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 181. JAPAN VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 182. JAPAN VACCINES MARKET SIZE, BY VACCINE COMBINATION, 2018-2030 (USD MILLION)
  • TABLE 183. JAPAN VACCINES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 184. JAPAN VACCINES MARKET SIZE, BY VACCINE CLASSIFICATION, 2018-2030 (USD MILLION)
  • TABLE 185. JAPAN VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 186. JAPAN VACCINES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 187. JAPAN VACCINES MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 188. JAPAN VACCINES MARKET SIZE, BY NON-INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 189. JAPAN VACCINES MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 190. JAPAN VACCINES MARKET SIZE, BY PEDIATRIC, 2018-2030 (USD MILLION)
  • TABLE 191. JAPAN VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 192. MALAYSIA VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 193. MALAYSIA VACCINES MARKET SIZE, BY VACCINE COMBINATION, 2018-2030 (USD MILLION)
  • TABLE 194. MALAYSIA VACCINES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 195. MALAYSIA VACCINES MARKET SIZE, BY VACCINE CLASSIFICATION, 2018-2030 (USD MILLION)
  • TABLE 196. MALAYSIA VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 197. MALAYSIA VACCINES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 198. MALAYSIA VACCINES MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 199. MALAYSIA VACCINES MARKET SIZE, BY NON-INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 200. MALAYSIA VACCINES MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 201. MALAYSIA VACCINES MARKET SIZE, BY PEDIATRIC, 2018-2030 (USD MILLION)
  • TABLE 202. MALAYSIA VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 203. PHILIPPINES VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 204. PHILIPPINES VACCINES MARKET SIZE, BY VACCINE COMBINATION, 2018-2030 (USD MILLION)
  • TABLE 205. PHILIPPINES VACCINES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 206. PHILIPPINES VACCINES MARKET SIZE, BY VACCINE CLASSIFICATION, 2018-2030 (USD MILLION)
  • TABLE 207. PHILIPPINES VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 208. PHILIPPINES VACCINES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 209. PHILIPPINES VACCINES MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 210. PHILIPPINES VACCINES MARKET SIZE, BY NON-INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 211. PHILIPPINES VACCINES MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 212. PHILIPPINES VACCINES MARKET SIZE, BY PEDIATRIC, 2018-2030 (USD MILLION)
  • TABLE 213. PHILIPPINES VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 214. SINGAPORE VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 215. SINGAPORE VACCINES MARKET SIZE, BY VACCINE COMBINATION, 2018-2030 (USD MILLION)
  • TABLE 216. SINGAPORE VACCINES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 217. SINGAPORE VACCINES MARKET SIZE, BY VACCINE CLASSIFICATION, 2018-2030 (USD MILLION)
  • TABLE 218. SINGAPORE VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 219. SINGAPORE VACCINES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 220. SINGAPORE VACCINES MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 221. SINGAPORE VACCINES MARKET SIZE, BY NON-INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 222. SINGAPORE VACCINES MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 223. SINGAPORE VACCINES MARKET SIZE, BY PEDIATRIC, 2018-2030 (USD MILLION)
  • TABLE 224. SINGAPORE VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 225. SOUTH KOREA VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 226. SOUTH KOREA VACCINES MARKET SIZE, BY VACCINE COMBINATION, 2018-2030 (USD MILLION)
  • TABLE 227. SOUTH KOREA VACCINES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 228. SOUTH KOREA VACCINES MARKET SIZE, BY VACCINE CLASSIFICATION, 2018-2030 (USD MILLION)
  • TABLE 229. SOUTH KOREA VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 230. SOUTH KOREA VACCINES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 231. SOUTH KOREA VACCINES MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 232. SOUTH KOREA VACCINES MARKET SIZE, BY NON-INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 233. SOUTH KOREA VACCINES MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 234. SOUTH KOREA VACCINES MARKET SIZE, BY PEDIATRIC, 2018-2030 (USD MILLION)
  • TABLE 235. SOUTH KOREA VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 236. TAIWAN VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 237. TAIWAN VACCINES MARKET SIZE, BY VACCINE COMBINATION, 2018-2030 (USD MILLION)
  • TABLE 238. TAIWAN VACCINES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 239. TAIWAN VACCINES MARKET SIZE, BY VACCINE CLASSIFICATION, 2018-2030 (USD MILLION)
  • TABLE 240. TAIWAN VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 241. TAIWAN VACCINES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 242. TAIWAN VACCINES MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 243. TAIWAN VACCINES MARKET SIZE, BY NON-INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 244. TAIWAN VACCINES MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 245. TAIWAN VACCINES MARKET SIZE, BY PEDIATRIC, 2018-2030 (USD MILLION)
  • TABLE 246. TAIWAN VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 247. THAILAND VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 248. THAILAND VACCINES MARKET SIZE, BY VACCINE COMBINATION, 2018-2030 (USD MILLION)
  • TABLE 249. THAILAND VACCINES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 250. THAILAND VACCINES MARKET SIZE, BY VACCINE CLASSIFICATION, 2018-2030 (USD MILLION)
  • TABLE 251. THAILAND VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 252. THAILAND VACCINES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 253. THAILAND VACCINES MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 254. THAILAND VACCINES MARKET SIZE, BY NON-INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 255. THAILAND VACCINES MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 256. THAILAND VACCINES MARKET SIZE, BY PEDIATRIC, 2018-2030 (USD MILLION)
  • TABLE 257. THAILAND VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 258. VIETNAM VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 259. VIETNAM VACCINES MARKET SIZE, BY VACCINE COMBINATION, 2018-2030 (USD MILLION)
  • TABLE 260. VIETNAM VACCINES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 261. VIETNAM VACCINES MARKET SIZE, BY VACCINE CLASSIFICATION, 2018-2030 (USD MILLION)
  • TABLE 262. VIETNAM VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 263. VIETNAM VACCINES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 264. VIETNAM VACCINES MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 265. VIETNAM VACCINES MARKET SIZE, BY NON-INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 266. VIETNAM VACCINES MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 267. VIETNAM VACCINES MARKET SIZE, BY PEDIATRIC, 2018-2030 (USD MILLION)
  • TABLE 268. VIETNAM VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 269. EUROPE, MIDDLE EAST & AFRICA VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 270. EUROPE, MIDDLE EAST & AFRICA VACCINES MARKET SIZE, BY VACCINE COMBINATION, 2018-2030 (USD MILLION)
  • TABLE 271. EUROPE, MIDDLE EAST & AFRICA VACCINES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 272. EUROPE, MIDDLE EAST & AFRICA VACCINES MARKET SIZE, BY VACCINE CLASSIFICATION, 2018-2030 (USD MILLION)
  • TABLE 273. EUROPE, MIDDLE EAST & AFRICA VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 274. EUROPE, MIDDLE EAST & AFRICA VACCINES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 275. EUROPE, MIDDLE EAST & AFRICA VACCINES MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 276. EUROPE, MIDDLE EAST & AFRICA VACCINES MARKET SIZE, BY NON-INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 277. EUROPE, MIDDLE EAST & AFRICA VACCINES MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 278. EUROPE, MIDDLE EAST & AFRICA VACCINES MARKET SIZE, BY PEDIATRIC, 2018-2030 (USD MILLION)
  • TABLE 279. EUROPE, MIDDLE EAST & AFRICA VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 280. EUROPE, MIDDLE EAST & AFRICA VACCINES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 281. DENMARK VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 282. DENMARK VACCINES MARKET SIZE, BY VACCINE COMBINATION, 2018-2030 (USD MILLION)
  • TABLE 283. DENMARK VACCINES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 284. DENMARK VACCINES MARKET SIZE, BY VACCINE CLASSIFICATION, 2018-2030 (USD MILLION)
  • TABLE 285. DENMARK VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 286. DENMARK VACCINES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 287. DENMARK VACCINES MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 288. DENMARK VACCINES MARKET SIZE, BY NON-INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 289. DENMARK VACCINES MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 290. DENMARK VACCINES MARKET SIZE, BY PEDIATRIC, 2018-2030 (USD MILLION)
  • TABLE 291. DENMARK VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 292. EGYPT VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 293. EGYPT VACCINES MARKET SIZE, BY VACCINE COMBINATION, 2018-2030 (USD MILLION)
  • TABLE 294. EGYPT VACCINES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 295. EGYPT VACCINES MARKET SIZE, BY VACCINE CLASSIFICATION, 2018-2030 (USD MILLION)
  • TABLE 296. EGYPT VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 297. EGYPT VACCINES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 298. EGYPT VACCINES MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 299. EGYPT VACCINES MARKET SIZE, BY NON-INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 300. EGYPT VACCINES MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 301. EGYPT VACCINES MARKET SIZE, BY PEDIATRIC, 2018-2030 (USD MILLION)
  • TABLE 302. EGYPT VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 303. FINLAND VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 304. FINLAND VACCINES MARKET SIZE, BY VACCINE COMBINATION, 2018-2030 (USD MILLION)
  • TABLE 305. FINLAND VACCINES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 306. FINLAND VACCINES MARKET SIZE, BY VACCINE CLASSIFICATION, 2018-2030 (USD MILLION)
  • TABLE 307. FINLAND VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 308. FINLAND VACCINES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 309. FINLAND VACCINES MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 310. FINLAND VACCINES MARKET SIZE, BY NON-INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 311. FINLAND VACCINES MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 312. FINLAND VACCINES MARKET SIZE, BY PEDIATRIC, 2018-2030 (USD MILLION)
  • TABLE 313. FINLAND VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 314. FRANCE VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 315. FRANCE VACCINES MARKET SIZE, BY VACCINE COMBINATION, 2018-2030 (USD MILLION)
  • TABLE 316. FRANCE VACCINES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 317. FRANCE VACCINES MARKET SIZE, BY VACCINE CLASSIFICATION, 2018-2030 (USD MILLION)
  • TABLE 318. FRANCE VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 319. FRANCE VACCINES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 320. FRANCE VACCINES MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 321. FRANCE VACCINES MARKET SIZE, BY NON-INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 322. FRANCE VACCINES MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 323. FRANCE VACCINES MARKET SIZE, BY PEDIATRIC, 2018-2030 (USD MILLION)
  • TABLE 324. FRANCE VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 325. GERMANY VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 326. GERMANY VACCINES MARKET SIZE, BY VACCINE COMBINATION, 2018-2030 (USD MILLION)
  • TABLE 327. GERMANY VACCINES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 328. GERMANY VACCINES MARKET SIZE, BY VACCINE CLASSIFICATION, 2018-2030 (USD MILLION)
  • TABLE 329. GERMANY VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 330. GERMANY VACCINES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 331. GERMANY VACCINES MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 332. GERMANY VACCINES MARKET SIZE, BY NON-INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 333. GERMANY VACCINES MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 334. GERMANY VACCINES MARKET SIZE, BY PEDIATRIC, 2018-2030 (USD MILLION)
  • TABLE 335. GERMANY VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 336. ISRAEL VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 337. ISRAEL VACCINES MARKET SIZE, BY VACCINE COMBINATION, 2018-2030 (USD MILLION)
  • TABLE 338. ISRAEL VACCINES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 339. ISRAEL VACCINES MARKET SIZE, BY VACCINE CLASSIFICATION, 2018-2030 (USD MILLION)
  • TABLE 340. ISRAEL VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 341. ISRAEL VACCINES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 342. ISRAEL VACCINES MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 343. ISRAEL VACCINES MARKET SIZE, BY NON-INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 344. ISRAEL VACCINES MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 345. ISRAEL VACCINES MARKET SIZE, BY PEDIATRIC, 2018-2030 (USD MILLION)
  • TABLE 346. ISRAEL VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 347. ITALY VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 348. ITALY VACCINES MARKET SIZE, BY VACCINE COMBINATION, 2018-2030 (USD MILLION)
  • TABLE 349. ITALY VACCINES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 350. ITALY VACCINES MARKET SIZE, BY VACCINE CLASSIFICATION, 2018-2030 (USD MILLION)
  • TABLE 351. ITALY VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 352. ITALY VACCINES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 353. ITALY VACCINES MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 354. ITALY VACCINES MARKET SIZE, BY NON-INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 355. ITALY VACCINES MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 356. ITALY VACCINES MARKET SIZE, BY PEDIATRIC, 2018-2030 (USD MILLION)
  • TABLE 357. ITALY VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 358. NETHERLANDS VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 359. NETHERLANDS VACCINES MARKET SIZE, BY VACCINE COMBINATION, 2018-2030 (USD MILLION)
  • TABLE 360. NETHERLANDS VACCINES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 361. NETHERLANDS VACCINES MARKET SIZE, BY VACCINE CLASSIFICATION, 2018-2030 (USD MILLION)
  • TABLE 362. NETHERLANDS VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 363. NETHERLANDS VACCINES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 364. NETHERLANDS VACCINES MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 365. NETHERLANDS VACCINES MARKET SIZE, BY NON-INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 366. NETHERLANDS VACCINES MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 367. NETHERLANDS VACCINES MARKET SIZE, BY PEDIATRIC, 2018-2030 (USD MILLION)
  • TABLE 368. NETHERLANDS VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 369. NIGERIA VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 370. NIGERIA VACCINES MARKET SIZE, BY VACCINE COMBINATION, 2018-2030 (USD MILLION)
  • TABLE 371. NIGERIA VACCINES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 372. NIGERIA VACCINES MARKET SIZE, BY VACCINE CLASSIFICATION, 2018-2030 (USD MILLION)
  • TABLE 373. NIGERIA VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 374. NIGERIA VACCINES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 375. NIGERIA VACCINES MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 376. NIGERIA VACCINES MARKET SIZE, BY NON-INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 377. NIGERIA VACCINES MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 378. NIGERIA VACCINES MARKET SIZE, BY PEDIATRIC, 2018-2030 (USD MILLION)
  • TABLE 379. NIGERIA VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 380. NORWAY VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 381. NORWAY VACCINES MARKET SIZE, BY VACCINE COMBINATION, 2018-2030 (USD MILLION)
  • TABLE 382. NORWAY VACCINES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 383. NORWAY VACCINES MARKET SIZE, BY VACCINE CLASSIFICATION, 2018-2030 (USD MILLION)
  • TABLE 384. NORWAY VACCINES MAR